Asthma

Studies show that more than 90% of EoE patients improve symptoms with food elimination therapy. Should more patients be in touch with allergists?

This is the third indication for the biologic therapy, following its approvals for adult AD and moderate to severe asthma maintenance care.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

According to investigators, recent trial results indicate no other biologic treatment has shown as rapid onset than benralizumab for patients with eosinophilic asthma.

Investigators sought to evaluate the efficacy, safety, psychosocial impact, quality of life, adherence to and satisfaction with the treatment of dupilumab and add-on treatment.

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

In this phase 3 study, dupilumab improved outcomes for patients with recurring severe chronic rhinosinusitis with nasal polyps.

What does the typical patient have to treat aside from their allergy, and what are their treatment goals?

Have current guidelines been fitted to consider the future of immunotherapy research?